_256_384.jpg)
Drug Approval | April 14, 2024
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Both organisations enter into a long- term collaboration to expand patient access in India
Vision loss due to Glaucoma can be prevented if it is detected and treated early
ANVISA issues CGMP to Concord Biotech’s Unit I
Dr Sheth's will commission a Healthmobile on Wheels initiative to ensure that healthcare doesn't remain confined to urban centers
Subscribe To Our Newsletter & Stay Updated
